Cargando…
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multice...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386707/ https://www.ncbi.nlm.nih.gov/pubmed/37514025 http://dx.doi.org/10.3390/pharmaceutics15071838 |
_version_ | 1785081734208946176 |
---|---|
author | Nomoto, Hiroshi Kito, Kenichi Iesaka, Hiroshi Oe, Yuki Kawata, Shinichiro Tsuchida, Kazuhisa Yanagiya, Shingo Miya, Aika Kameda, Hiraku Cho, Kyu Yong Sakuma, Ichiro Manda, Naoki Nakamura, Akinobu Atsumi, Tatsuya |
author_facet | Nomoto, Hiroshi Kito, Kenichi Iesaka, Hiroshi Oe, Yuki Kawata, Shinichiro Tsuchida, Kazuhisa Yanagiya, Shingo Miya, Aika Kameda, Hiraku Cho, Kyu Yong Sakuma, Ichiro Manda, Naoki Nakamura, Akinobu Atsumi, Tatsuya |
author_sort | Nomoto, Hiroshi |
collection | PubMed |
description | Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia. The subanalysis included participants who did not change their treatment for diabetes and did not receive insulin or insulin secretagogues during the study period. Changes in glucose metabolism markers, including homeostatic model assessment (HOMA2) scores and disposition index, were assessed. A total of 279 participants (141 in the pemafibrate group; 138 in the control group) met the criteria for the subanalysis. There were no significant changes in HbA1c during the 52-week study period in both groups. However, the pemafibrate group showed significant improvements versus the control group for insulin resistance assessed by HOMA2-R (−0.15 versus 0.08; estimated treatment difference −0.23 (95% confidence interval −0.44, −0.02); p = 0.03) and maintenance of β-cell function assessed by disposition index (0.015 versus −0.023; estimated treatment difference 0.037 (95% confidence interval 0.005, 0.069); p = 0.02). Correlation analyses showed that improvements in HOMA2-R and disposition index were significantly associated with improvements in lipid abnormalities and γ-glutamyl transpeptidase. In conclusion, pemafibrate reduced insulin resistance and maintained β-cell function in subjects with T2DM and hypertriglyceridemia, presumably by improving lipid profiles and lipid-related hepatocyte stress. |
format | Online Article Text |
id | pubmed-10386707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103867072023-07-30 Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study Nomoto, Hiroshi Kito, Kenichi Iesaka, Hiroshi Oe, Yuki Kawata, Shinichiro Tsuchida, Kazuhisa Yanagiya, Shingo Miya, Aika Kameda, Hiraku Cho, Kyu Yong Sakuma, Ichiro Manda, Naoki Nakamura, Akinobu Atsumi, Tatsuya Pharmaceutics Article Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This was a subanalysis of the PARM-T2D study, a multicenter prospective observational study on the use of pemafibrate versus conventional therapy for 52 weeks in subjects with T2DM complicated with hypertriglyceridemia. The subanalysis included participants who did not change their treatment for diabetes and did not receive insulin or insulin secretagogues during the study period. Changes in glucose metabolism markers, including homeostatic model assessment (HOMA2) scores and disposition index, were assessed. A total of 279 participants (141 in the pemafibrate group; 138 in the control group) met the criteria for the subanalysis. There were no significant changes in HbA1c during the 52-week study period in both groups. However, the pemafibrate group showed significant improvements versus the control group for insulin resistance assessed by HOMA2-R (−0.15 versus 0.08; estimated treatment difference −0.23 (95% confidence interval −0.44, −0.02); p = 0.03) and maintenance of β-cell function assessed by disposition index (0.015 versus −0.023; estimated treatment difference 0.037 (95% confidence interval 0.005, 0.069); p = 0.02). Correlation analyses showed that improvements in HOMA2-R and disposition index were significantly associated with improvements in lipid abnormalities and γ-glutamyl transpeptidase. In conclusion, pemafibrate reduced insulin resistance and maintained β-cell function in subjects with T2DM and hypertriglyceridemia, presumably by improving lipid profiles and lipid-related hepatocyte stress. MDPI 2023-06-27 /pmc/articles/PMC10386707/ /pubmed/37514025 http://dx.doi.org/10.3390/pharmaceutics15071838 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nomoto, Hiroshi Kito, Kenichi Iesaka, Hiroshi Oe, Yuki Kawata, Shinichiro Tsuchida, Kazuhisa Yanagiya, Shingo Miya, Aika Kameda, Hiraku Cho, Kyu Yong Sakuma, Ichiro Manda, Naoki Nakamura, Akinobu Atsumi, Tatsuya Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title_full | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title_fullStr | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title_full_unstemmed | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title_short | Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study |
title_sort | favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the parm-t2d study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386707/ https://www.ncbi.nlm.nih.gov/pubmed/37514025 http://dx.doi.org/10.3390/pharmaceutics15071838 |
work_keys_str_mv | AT nomotohiroshi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT kitokenichi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT iesakahiroshi favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT oeyuki favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT kawatashinichiro favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT tsuchidakazuhisa favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT yanagiyashingo favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT miyaaika favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT kamedahiraku favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT chokyuyong favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT sakumaichiro favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT mandanaoki favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT nakamuraakinobu favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy AT atsumitatsuya favorableeffectofpemafibrateoninsulinresistanceandbcellfunctioninsubjectswithtype2diabetesandhypertriglyceridemiaasubanalysisoftheparmt2dstudy |